News stories about Astrazeneca PLC (NYSE:AZN) have been trending positive this week, according to AlphaOne Sentiment Analysis. The research firm, a unit of Accern, scores the sentiment of press coverage by monitoring more than twenty million news and blog sources. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Astrazeneca PLC earned a media sentiment score of 0.26 on AlphaOne’s scale. AlphaOne also gave news articles about the company an impact score of 85 out of 100, meaning that recent press coverage is very likely to have an impact on the stock’s share price in the next several days.
These are some of the media stories that may have impacted AlphaOne Sentiment Analysis’s scoring:
- Astrazeneca PLC (AZN) Stake Increased by Azimuth Capital Management LLC (leisuretravelaid.com)
- Astrazeneca PLC (AZN) Position Increased by Becker Capital Management Inc (naijaoversabi.com)
- Can AstraZeneca Keep Up As Clovis, Tesaro Unveil Blockbuster Drugs? (finance.yahoo.com)
- Astrazeneca PLC Target of Unusually Large Options Trading (AZN) (americanbankingnews.com)
- [$$] European takeover rules merit a sceptical response (finance.yahoo.com)
AZN has been the topic of several recent analyst reports. HSBC Holdings plc downgraded shares of Astrazeneca PLC from a “hold” rating to a “reduce” rating in a report on Friday, April 7th. TheStreet raised shares of Astrazeneca PLC from a “c+” rating to a “b-” rating in a research note on Tuesday, February 28th. Liberum Capital started coverage on shares of Astrazeneca PLC in a research report on Thursday, March 9th. They set a “buy” rating for the company. Cowen and Company restated a “market perform” rating on shares of Astrazeneca PLC in a research report on Monday, March 6th. Finally, Barclays PLC started coverage on shares of Astrazeneca PLC in a research report on Tuesday, March 7th. They set an “overweight” rating for the company. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $35.84.
Astrazeneca PLC (NYSE:AZN) traded up 1.26% on Friday, reaching $34.54. 2,511,306 shares of the company’s stock were exchanged. The firm’s 50 day moving average is $33.17 and its 200 day moving average is $29.89. The stock has a market capitalization of $87.46 billion, a P/E ratio of 25.87 and a beta of 0.81. Astrazeneca PLC has a 1-year low of $25.55 and a 1-year high of $35.27. Astrazeneca PLC also was the recipient of unusually large options trading on Tuesday. Stock investors acquired 11,305 put options on the company. This is an increase of approximately 809% compared to the typical daily volume of 1,244 put options.
Astrazeneca PLC (NYSE:AZN) last issued its quarterly earnings results on Thursday, April 27th. The company reported $0.99 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.38 by $0.61. The firm had revenue of $5.41 billion for the quarter, compared to analysts’ expectations of $5.40 billion. Astrazeneca PLC had a return on equity of 35.65% and a net margin of 15.21%. Astrazeneca PLC’s revenue was down 11.6% on a year-over-year basis. During the same quarter last year, the business posted $0.95 EPS. Analysts expect that Astrazeneca PLC will post $1.86 EPS for the current year.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/positive-media-coverage-very-likely-to-impact-astrazeneca-plc-azn-share-price/1916144.html
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.